Testosterone pellets for women: what the evidence says about control and dosing

What did @healing.endo.meno actually say?

After five years on various hormone replacement therapy (HRT) forms, this creator says testosterone pellets gave her a short honeymoon phase before triggering hair loss, weight gain, mood swings, and paradoxically, lower libido. Her core argument: pellets lock you into a three-month delivery window with no way to adjust if things go wrong. She now prefers injections for dose control, and recommends newer users start with patches or creams rather than pellets.

She also raises a specific clinical complaint: her provider gave her testosterone instead of estrogen, essentially using testosterone "to compensate" for estrogen she wasn't receiving. She names spironolactone as a mitigation option for hair loss and water retention in women on testosterone.

Does the science back this up?

More than you might expect. The irreversibility concern with pellets is real and documented. High-dose testosterone in women does carry the side effect profile she describes, and the lack of flexible dosing with subcutaneous pellets is a legitimate clinical limitation.

Subcutaneous testosterone pellets in women have been associated with supraphysiologic testosterone levels in a meaningful subset of patients. A 2019 study by Glaser et al. in Maturitas reported that pellet dosing variability can produce testosterone levels well above the normal female range, with symptomatic androgenic effects including acne, hair thinning, and mood disturbance. The pharmacokinetics of pellets are notoriously difficult to predict because absorption rates depend on physical activity, body composition, and vascular density at the insertion site.

Her claim that pellets have driven the recent surge in testosterone prescribing for women has indirect support. Analysis of U.S. prescription trends shows testosterone prescriptions for women rose sharply after pellet therapy expanded in the 2010s, though separating pellet-specific prescribing from broader HRT trends is difficult.

What did they get wrong (or right)?

She got the core side-effect profile right. She got a few mechanistic details muddled. The claim that providers use testosterone "to compensate for estrogen" is not standard clinical practice and warrants skepticism. Testosterone does not substitute for estradiol in any established clinical guideline.

The Endocrine Society's 2023 clinical practice guideline for female hypoactive sexual desire disorder recommends testosterone only as an adjunct, not a replacement for estrogen therapy in perimenopausal women. If her provider was genuinely substituting testosterone for estradiol, that is a clinical misstep, not an industry standard.

Her statement that "before pellets, HRT wasn't as much testosterone" is roughly accurate as a cultural observation but not a clinical one. Testosterone has been studied in women since the 1940s. The pellet industry commercialized it more aggressively, not invented it.

Her spironolactone mention is clinically reasonable. Spironolactone is an anti-androgen used off-label to manage androgenic side effects, and its use as a counterbalance in women on testosterone therapy is supported by dermatology and endocrinology practice, though robust randomized trial data specific to this context remains thin.

What should you actually know?

Testosterone therapy for women is not well-regulated in the United States. There is no FDA-approved testosterone product for women in the U.S. as of 2024. Everything is off-label, which means dosing, delivery method, and monitoring standards vary enormously by provider.

The irreversibility window of pellets is a legitimate patient safety concern. If you develop supraphysiologic testosterone levels from a pellet, you cannot simply stop the medication. You wait it out, usually 3 to 4 months. Topical preparations (gels, creams) or injections allow faster dose adjustment, which is a real clinical advantage for women who are dose-sensitive.

A 2022 review by Davis et al. in The Lancet Diabetes and Endocrinology found that while testosterone therapy in women shows benefit for hypoactive sexual desire disorder, evidence for broader symptom relief in perimenopause is limited, and safety data beyond 24 months is insufficient. Individualized dosing and regular monitoring of serum testosterone levels are considered essential.

The creator's recommendation to start with adjustable delivery systems before committing to pellets is consistent with a cautious, patient-first approach. It is not a universal clinical rule, but it is reasonable advice for someone who does not yet know how their body responds to exogenous testosterone.